Business Wire

Insulet Corporation Presents Real-World Clinical Data on the Use of Its Omnipod® Insulin Management System in Approximately 39,000 Patients Using a Cloud-Based Data Management System

Del

Insulet Corporation (NASDAQ:PODD) (Insulet or the Company), the leader in tubeless insulin pump technology with its Omnipod® Insulin Management System (Omnipod System), today presented real-world clinical data at the Congress of the European Association for the Study of Diabetes (EASD) in Lisbon, Portugal.

This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170913005204/en/

The data are from a study of 38,778 patients in the United States with type 1 and type 2 diabetes who received insulin using the Omnipod System with at least three months of data downloaded using Insulet Provided Glooko (a cloud-based diabetes data management system). The data demonstrated this use was associated with frequent fingerstick blood glucose testing through the integrated Abbott FreeStyle® glucose meter and high usage of the advanced features of the Omnipod System.1 These findings provide meaningful insights into patient behaviors and clinical outcomes that can be used to positively impact treatment decisions.

“These data represent a large portion of our U.S. customer base and provide valuable insights into patient behaviors and clinical outcomes in the real-world setting,” said Dr. Trang Ly, Vice President and Medical Director at Insulet. “Our partnership with Glooko provides meaningful input into self-management patterns and blood glucose profiles, which inform our future innovation and allow clinicians to better care for their patients. We are excited about these positive results further evidencing the many benefits of our Omnipod System and we look forward to presenting additional details at the EASD meeting.”

Insulet will present at its sponsored symposium at the EASD meeting on Thursday, September 14, 2017 at 7 p.m. local time.

A number of clinical variables were analyzed which provided a valuable benchmark regarding Omnipod user insulin management behaviors. The average glucose level was 186 mg/dL, which is equivalent to an estimated HbA1C of 8.1%. This compares favorably to recent reports of U.S. data from the Type 1 Diabetes Exchange Registry demonstrating an average HbA1C of 8.4%2. In addition, the data demonstrated advanced pump feature use (e.g., extended bolus feature) occurred in 36% of all patients.

A subset of 3,394 people in the study used a continuous glucose monitor (CGM) in addition to the Omnipod System and additional variables were analyzed for this group. A larger percentage of CGM plus Omnipod users required less insulin and spent more time in the normal range (70-180 mg/dL), and less time in the hypoglycemic and hyperglycemic ranges. A much higher percentage (65%) of the CGM plus Omnipod group used advanced Omnipod System features, supporting the potential for additional blood glucose data to positively impact insulin management behaviors, especially when combined with the use of the Omnipod System.

These initial data are promising and there is the potential for additional areas of invaluable insight in different markets, notably Europe, and specifically once Insulet assumes responsibility for the distribution and commercial support of Omnipod in Europe on July 1, 2018. Establishing this direct European presence will allow the Company to be closer to the local diabetes community to deepen its understanding of customer behaviors and incorporate these learnings to drive strong customer support and innovation.

“The ability for Insulet to deliver this level of insight through real-world data in patients using an insulin pump, continuous glucose monitoring and a data management system is impressive and represents a very promising platform for the development of future innovation,” said Professor Eric Renard, Head of Department, Department of Endocrinology, Diabetes and Nutrition, Montpellier University Hospital, France.

1 Schütt M, et al. Is the frequency of self-monitoring of blood glucose related to long-term metabolic control? Multicenter analysis including 24,500 patients from 191 centers in Germany and Austria. Exp Clin Endocrinol Diabetes. 2006.

2 Miller KM, et al. Current state of type 1 diabetes treatment in the US: updated data from the T1D Exchange clinic registry. Diabetes Care. 2015;38(6)971-978.

About the Omnipod Insulin Management System:

The Omnipod Insulin Management System is an innovative continuous insulin delivery system that provides all the proven benefits of continuous subcutaneous insulin infusion (CSII) therapy in a way no conventional insulin pump can. The Omnipod System's innovative design and features allows people living with diabetes to live their life—and manage their diabetes—with unprecedented freedom, comfort, convenience, and ease. The Omnipod System consists of two components: (i) a Pod that stores and delivers insulin; and (ii) a Personal Diabetes Manager (PDM) that wirelessly programs the user's personalized insulin delivery, calculates suggested doses and insulin on board, and has a convenient, built-in blood glucose meter. The small, light-weight Pod can be worn in multiple locations, including the abdomen, hip, back of upper arm, upper thigh or lower back and, because it is waterproof (IPX8), there is no need to remove when showering, swimming or performing other activities. This means that Omnipod can provide up to three days of non-stop insulin delivery, without the need to disconnect a tube set or manually inject insulin. The Pod and PDM communicate wirelessly to offer precise, personalized and continuous insulin delivery with customizable basal and bolus delivery options, as well as important safety checks. The Pod's auto-cannula insertion is quick, simple, and virtually pain-free. Users never have to handle a needle. The user simply pushes a button on the PDM and the Pod's automated insertion system inserts the cannula beneath the skin and begins delivering insulin according to the user's programmed basal rate.

The Omnipod System is the world's first commercially available tubeless insulin delivery system that allows users to live untethered by tubing and without the stress and anxiety of multiple daily injections. By breaking down the barriers to insulin pump therapy, the Omnipod System offers freedom for users to live life on their own terms and with the ease of use they deserve.

About Insulet Corporation:

Insulet Corporation (NASDAQ: PODD) is an innovative medical device company dedicated to making the lives of people with diabetes easier. Insulet seeks to expand the use of insulin pump therapy with its Omnipod Insulin Management System among people with insulin-dependent diabetes. The Omnipod System is a revolutionary and easy-to-use tubeless insulin pump that provides up to three days of non-stop insulin delivery, without the need to see or handle a needle. Insulet's Delivery Systems business partners with global pharmaceutical and biotechnology companies to adapt the Omnipod technology platform for the delivery of subcutaneous drugs across multiple therapeutic areas. Founded in 2000, Insulet Corporation is based in Billerica, Massachusetts. For more information, please visit: http://www.myomnipod.com.

Forward-Looking Statement:

This press release may contain forward-looking statements concerning Insulet's expectations, anticipations, intentions, beliefs or strategies regarding the future. These forward-looking statements are based on its current expectations and beliefs concerning future developments and their potential effects on Insulet. There can be no assurance that future developments affecting Insulet will be those that it has anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond its control) or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements, and other risks and uncertainties described in its Annual Report on Form 10-K, which was filed with the Securities and Exchange Commission on February 28, 2017 in the section entitled "Risk Factors," and in its other filings from time to time with the Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should any of its assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. Insulet undertakes no obligation to publicly update or revise any forward-looking statements.

© 2017 Insulet Corporation and Omnipod are trademarks or registered trademarks of Insulet Corporation. All rights reserved. All other trademarks are the property of their respective owners. The use of third party trademarks does not constitute an endorsement or imply a relationship or other affiliation.

Contact information

Investor Relations and Corporate Media Contact:
Insulet Corporation
Deborah R. Gordon, 978 600-7717
Vice President, Investor Relations and Corporate Communications
dgordon@insulet.com

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

OpenGate Capital Launches OGx Digital Transformation Capability16.1.2019 08:00Pressemelding

OpenGate Capital, a global private equity firm, announced today that it has launched OGx, a newly formed digital innovation and business transformation growth capability as part of the firm’s commitment to untap the full potential of its acquired businesses. Developed during 2018, OGx represents the combined power of the firm’s operational excellence best practices with applied exponential technologies and business model innovation to yield the XPotential™ for select investments. Andrew Nikou, OpenGate Capital’s founder and CEO stated, “We are constantly looking for innovative and differentiated ways to accelerate profitable growth in the businesses we acquire. We are excited to launch OGx after successfully piloting it during 2018, recognizing that in this age of increased technology and business disruption, sustainable and scalable value creation within our holding period must go well beyond traditional operating drivers. We believe that a great deal of upside can be created from tak

Gemalto to Produce Secure and Innovative Healthcare Cards for Quebec16.1.2019 06:00Pressemelding

Gemalto (Euronext NL0000400653 - GTO), the world leader in digital security, and the Société de l'assurance automobile du Québec (SAAQ) have been chosen to produce secure and innovative health insurance cards for the Régie de l'assurance maladie du Québec (RAMQ). RAMQ delivers 2.3 million healthcare cards to citizens, and the SAAQ provides 1.7 million driver’s license and identity cards through production with Gemalto. Optimizing government services across industries By choosing the SAAQ and its existing contract with Gemalto, the Quebec healthcare authorities can avoid duplication and promote sharing of expertise between agencies. The province can also leverage the existing infrastructure and issue both healthcare cards and driver’s licenses at the same time, maximizing cost savings and ensuring quicker delivery to their citizens. A focus on security and convenience for Quebec’s citizens Gemalto’s secure card will be the first of its kind to undergo embossing and laser engraving at th

Stewart Title Ltd. Appoints Ferky Azib to General Counsel and Corporate Secretary16.1.2019 05:00Pressemelding

Stewart Title Ltd., the underwriter for Stewart’s transactions in the United Kingdom, Europe and Australia, announced today the promotion of Ferky Azib to General Counsel. In her new position, Ms. Azib will provide counsel and guidance on all legal matters for Stewart Title Limited’s expanding operations. She will be involved in the development and implementation of corporate policies as well as oversee corporate governance and regulatory compliance. Ms. Azib will also serve on the Stewart Title Limited Board of Directors as Corporate Secretary. “Ms. Azib has the knowledge and experience required to guide the company through all the regulatory requirements in the countries within which we operate,” said Steven Lessack, chief executive officer, Stewart Title Limited. “Equally important, she has developed an excellent rapport with both clients and staff, providing valued insight and support. It is a pleasure to have her on board as we move forward with our growth in this region.” Ms. Azi

PMC Group International Announces Acquisition of Product Line from Solvay, SA16.1.2019 00:33Pressemelding

PMC Ouvrie SAS, France, a wholly owned subsidiary of PMC Group International Inc., which is an independent arm of PMC Group Inc., announced the acquisition of a hydrocolloid product line from the Belgium based Solvay, SA. These products will be sold globally to the home and personal care (HPC), industrial and coatings markets under the trade names Rhodicare CFT, Rhodicare D, Rhodicare H, Rhodicare S, Rhodicare T, Rhodicare XC, Rhodopol 23, Rhodopol G, Rhodopol T, Rhodopol TG, Rhodopol Extra 2, and Rhodopol Extra 2 Clear. “The acquisition of these products made by fermentation processes emphasizes our increasing interest in products made by green chemistry and biological processes,” said Dr. Raj Chakrabarti, Head of PMC Group International. “The acquired hydrocolloids fit synergistically with the functional product lines of PMC Ouvrie, which has long been a leading supplier of defoamers to bio-based process technologies,” he added. ABOUT PMC PMC Group is a US based growth oriented, dive

TurbineAero, Inc. Announces Acquisition of APU Piece Part Repair Business from the Triumph Group15.1.2019 23:51Pressemelding

TurbineAero, a portfolio company of The Gores Group, announced today the acquisition of the APU piece part repair product line (“RPL”) from Triumph Aviation Services Asia, Ltd. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190115005959/en/ TurbineAero Repair–Asia, APU Operations Team (Photo: Business Wire) The acquisition of this business segment integrates APU piece part repair into the APU Systems MRO in TurbineAero’s Asia facility which increases in-house capabilities, improves turn-times and assures extra cost reduction. Effective immediately, the integration will take place in TurbineAero Asia’s new Thailand based 80,000 square foot facility which will house up to 250 employees and will handle high technological testing, maintenance, repair and overhaul activities for aircraft components and systems for our worldwide customers, including APU MRO, LRUs and APU part repair. “We are delighted to add the APU piece part rep

INDYCAR Names NTT as Entitlement Sponsor of IndyCar Series15.1.2019 17:20Pressemelding

INDYCAR announced today during the North American International Auto Show that global information technology and communications leader NTT has signed a multi-year agreement to become the IndyCar Series Title Partner. In addition, NTT becomes the Official Technology Partner of INDYCAR, the IndyCar® Series, Indianapolis Motor Speedway, the Indianapolis 500 and NASCAR’s the Brickyard 400 beginning in 2019. INDYCAR will partner with NTT to deliver digital innovations that enhance the fan experience. These innovations include the evolution of INDYCAR’s mobile application and adoption of NTT’s proprietary Smart Platform to support the sport and its venues in delivering better insights into the racing series. “NTT is proud to be associated with INDYCAR and accelerate the future of smart racing. Technological innovations have the potential to change the sport and fan experience drastically,” said Jun Sawada, President and CEO of NTT. “NTT, along with our partners, aims to bring the Smart World